177Lu-trastuzumab radionuclide therapy: a promising strategy for trastuzumab-resistant brain metastases in HER2+ breast cancer
Liliana Santos, Ivanna Hrynchak, José Sereno, Hugo R.S. Ferreira, Magda Silva, Alexandra Fonseca, Rui Almeida, Paulo Teixeira, Antero J. Abrunhosa, Célia M. F. Gomes · 2026
Read 177Lu-trastuzumab radionuclide therapy: a promising strategy for trastuzumab-resistant brain metastases in HER2+ breast cancer by Liliana Santos, Ivanna Hrynchak, José Sereno, Hugo R.S. Ferreira, Magda Silva, Alexandra Fonseca, Rui Almeida, Paulo Teixeira, Antero J. Abrunhosa, Célia M. F. Gomes (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13575020.txt.
Description
Breast cancer that spreads to the brain often learns to resist the main antibody drug aimed at its growth switch, leaving few options. Liliana Santos and co-authors test a radioactive twist on that same drug in a 2026 study. The antibody carries a radioactive metal, so it brings cell-killing rays straight to the lump instead of just blocking a signal.
Brain-homing cancer cells in dishes still carried the growth switch but no longer feared the plain drug. The radioactive version killed them anyway, by shredding their DNA. In mice, one dose shrank brain lumps and cleared them fully in a good share of cases, with no sign of brain harm. Scans also showed the drug reaches some brain lumps and not others, which could guide who gets the treatment.
Catalog record
| CREATOR | Liliana Santos, Ivanna Hrynchak, José Sereno, Hugo R.S. Ferreira, Magda Silva, Alexandra Fonseca, Rui Almeida, Paulo Teixeira, Antero J. Abrunhosa, Célia M. F. Gomes |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 59 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |